InnoCare Pharmaceuticals (HKEX: 09969), a leader in the fields of cancer and autoimmune diseases, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with urothelial cancer. ICP-192 is a potentially best-in-class highly selective small-molecule pan-FGFR inhibitor for the treatment of various solid tumors with FGFR aberrations. ICP-192 is currently undergoing Phase 1/2 studies in China and the United States.
The Phase 2 multi-center, single-arm, open-label clinical trial is designed to evaluate the safety and efficacy of ICP-192 in patients with advanced urothelial cancer that have FGFR aberrations in China.
“Urothelial cancer is a common malignant tumor in the urinary system, and FGFR aberrations happen in 20-30% of all urothelial cancer patients. Currently, there is a high unmet medical need for urothelial cancer in China. We’re keen to explore the profile of ICP-192 in this Phase 2 clinical trial in hope that we may bring patients with better treatment options.” said Dr. Guo Jun of the Beijing Cancer Hospital.
“ICP-192 is a highly selective pan-FGFR inhibitor developed by InnoCare Pharma.” said Dr. Jisong Cui, Co-founder, Chairman, and CEO of InnoCare. “This marks a significant milestone for us and we will continue to work with researchers to advance the clinical development of the drug. At InnoCare, we strive to provide patients with superior treatment options globally.”
About InnoCare Pharma
InnoCare Pharmaceuticals is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high incidence rates in the Chinese population. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.